Power Law company profile

Synthorx

Biotech & Life Sciences · San Diego, United States · Founded 2014 · IPO 2018 Unicorn

Biotechnology company using synthetic biology to synthesize solutions

Valuation

$2.50B

Market cap · 2026

Featured in Unicorn$1B+ valuation tier · Power Law dataset 2026

Investors

5 investors on Synthorx's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 2 investors entered at this stage

Avalon Ventures

Correlation Ventures

Series B+ 3 investors entered at this stage

RA Capital Management

Medicxi

OrbiMed

Global footprint

Where Synthorx has talent and traffic

Workforce by country

1 countries with
team presence

🇺🇸 United States100%

1 country shown

Patent intelligence

$32M patent portfolio · 30 active families

Estimated portfolio value

$32M

1.3% of market cap · 523.4× the top peer Tourmaline Bio ($60k)

30 active patent families

Where Synthorx innovates InterleukinPharmaceutical drugBiochemistryMolecular biologyPharmacology

Where Synthorx concentrates vs peers

Each axis is a top-10 topic across Synthorx and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about Synthorx

An AI-synthesized read of the highest-engagement posts about Synthorx on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Synthorx on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles